Iopofosine i-131 is a small molecule commercialized by Cellectar Biosciences, with a leading Phase II program in Refractory Multiple Myeloma. According to Globaldata, it is involved in 9 clinical trials, of which 3 were completed, and 6 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Iopofosine i-131’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Iopofosine i-131 is expected to reach an annual total of $156 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Iopofosine i-131 Overview

Iopofosine I-131 (CLR-131) is under development for the treatment of waldenstrom macroglobulinemia, refractory and relapsed multiple myeloma, chronic lymphocytic leukemia, Hodgkin lymphoma, small lymphocytic lymphoma, lymphoplasmacytic lymphoma (LPL), central nervous system lymphoma, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), solid tumors, neuroblastoma, pediatric diffuse intrinsic pontine glioma, sarcomas including rhabdomyosarcoma, Ewing's sarcoma, osteosarcoma, lymphomas and malignant brain tumors, high-grade glioma, diffuse large B-cell lymphoma (DLBCL), head and neck cancer squamous cell carcinoma. The drug candidate is radiolabeled compound administered through intravenous route in the form of solution. It comprises of PLE, 18-(p-[I-131] iodophenyl) octadecyl phosphocholine, covalently labelled with iodine-131. It is being developed based on Phospholipid Drug Conjugate (PDC) delivery platform.

It was also under development for the treatment of non-small cell lung cancer, breast cancer, soft tissue sarcoma, colorectal cancer, gastric cancer, prostate cancer, ovarian cancer and esophageal cancer.

Cellectar Biosciences Overview

Cellectar Biosciences (Cellectar), is a biopharmaceutical company that discovers, develops and commercializes drugs for treatment of cancer. The company’s proprietary technology, phospholipid drug conjugates (PDC) delivery platform develops PDCs for the treatment and diagnosis of cancer. Its lead product includes CLR 131, is a small-molecule PDC, in Phase II clinical trials for the treatment of relapse or refractory multiple myeloma and B-cell lymphomas. The company is also evaluating CLR 131 in Phase I clinical trials for treatment of Pediatric patients with solid tumors, lymphomas, malignant brain tumors, head and neck cancer. Cellectar’s other products in the pipeline include CLR 1800, CLR 1900, CLR 2000, CLR 2100, CLR 2200 and CLR 12120 for solid tumors and oncology indications. The company has collaborations with Orano Med, Onconova Therapeutics, Avicenna Oncology and University of Wisconsin. Cellectar is headquartered in Florham Park, New Jersey, the US.

For a complete picture of Iopofosine i-131’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 20 May 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.